Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAD51 as an immunohistochemistry-based marker of poly(ADP-ribose) polymerase inhibitor resistance in ovarian cancer

25 Apr 2024

Abstract excerpt

Objective Effective functional biomarkers that can be readily used in clinical practice to predict poly(ADP-ribose) polymerase inhibitor (PARPi) sensitivity are lacking. With the widespread adoption of PARPi maintenance therapy in ovarian cancer, particularly in patients with BRCA mutation or HR deficiencies, accurately identifying de novo or acquired resistance to PARPi has become critical in clinical practice....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Endometrial and Cervical Cancer Treatments
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38725623
DOI: 10.3389/fonc.2024.1351778

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAD51 as an immunohistochemistry-based marker of poly(ADP-ribose) polymerase inhibitor resistance in ovarian cancerPMID 38725623Read ↗

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient StratificationSemantic proximity Read ↗

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationSemantic proximity Read ↗

Predictive value of RAD51 on the survival and drug responsiveness of ovarian cancerSemantic proximity Read ↗

Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancerSemantic proximity Read ↗

Combining Homologous Recombination-Deficient Testing and Functional RAD51 Analysis Enhances the Prediction of Poly(ADP-Ribose) Polymerase Inhibitor SensitivitySemantic proximity Read ↗

RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?Semantic proximity Read ↗

Characterization of a RAD51C -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistanceSemantic proximity Read ↗

RAD21 Confers Poor Prognosis and Affects Ovarian Cancer Sensitivity to Poly(ADP-Ribose)Polymerase Inhibitors Through DNA Damage RepairSemantic proximity Read ↗

The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor BlocksSemantic proximity Read ↗

RAD51 as a potential surrogate marker for DNA repair capacity in solid malignanciesSemantic proximity Read ↗

Primary platinum resistance and immune exclusion in ovarian carcinomas with high expression of the homologous recombination mediator RAD51Semantic proximity Read ↗

PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanismsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.